HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
January 14, 2025
Host Chris Miglino interviews CEO Ilan Sobel. He talks about the way that their technology is used, the challenges that they face and how they make it economically viable.